For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for motor vehicle accidents (MVA) compared with continuous positive airway pressure (CPAP ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

Sleep apnea affects over 29 million Americans, with Obstructive Sleep Apnea (characterized by pauses in breathing during ...

While Continuous Positive Airway Pressure (CPAP) machines have long been the standard treatment, many patients find them uncomfortable or difficult to use. Fortunately, Sleep Solution Centers, a ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Sleep optimization, or, in other words, ‘sleepmaxxing,’ is getting trendy on social media among those prioritizing their sleep routine for some time already. From sleep trackers, mouth taping, nostril ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,569.2 Million by 2030.